PATENT CLAIM ANALYSIS

Application Number: 15969742
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "017700"]

Abstract:
This invention relates to methods of administering compounds containing selenium, selenocysteine, or a selenocysteine peptide to treat, for example, conditions associated with selenium deficiency, or ferroptoptic, parthanototic, and endoplasmic reticulum stress, and/or cancer. The methods of treatment may activate or inhibit (via TFAP2C and Sp1 proteins) the adaptive homeostatic response of the selenome. The compounds may contain a targeting sequence that causes them to be delivered to specific organs and/or tissues. The compounds may be administered, for example, orally, intranasally, intravenously, or by a minimally invasive catheter or BrainPath.

Claim (Index 48):
The method of  claim 30 , wherein the condition associated with a oxidative stress is a neuropsychiatric disorder.

Metadata:
- Claim Count in Document: 164.0
- Percentile: 93.0
- Lexical Diversity: 1.61194
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14414669', '15442475', '15111144', '11185859', '09856199']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7606774499416126
- 35 USC 102 Novelty (BERT): 0.5133327765244026
- Combined Prediction Score: 0.7359429825998915
- Mean Citation Score: 207.900706
- Max Citation Score: 226.71336
- Similarity Product: 128.97316057524205

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test